Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly, AstraZeneca, Cephalon Marketing Practices Under Review By House Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Rep. Waxman is requesting information into the marketing of Zyprexa, Seroquel, Actiq and Fentora.

You may also be interested in...



Cephalon Settles Federal Investigation Of Marketing Practices For $425 Million

Cephalon enters into a corporate integrity agreement with HHS Inspector General, which likely will be in line with its existing compliance program, firm tells “The Pink Sheet” DAILY.

Cephalon Settles Federal Investigation Of Marketing Practices For $425 Million

Cephalon enters into a corporate integrity agreement with HHS Inspector General, which likely will be in line with its existing compliance program, firm tells “The Pink Sheet” DAILY.

Cephalon Revises Fentora Labeling To Highlight Patient Selection Criteria Following Deaths

Among the deaths associated with the breakthrough cancer pain treatment were two patients prescribed the drug for migraines, Cephalon tells “The Pink Sheet” DAILY.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel